This week marks the 37th anniversary of the approval of human insulin – the first biotech drug ever. Almost as revolutionary as the drug was its five-month approval by the FDA, which was two years less than average. Dr. Henry Miller celebrates the dawn of biotechnology. He should know. At that time he was in charge of the FDA team that reviewed it.
The protection of intellectual property is vital to innovation. If anyone can just take something you created -- be it a song or a drug -- without proper compensation, there would be little reason to develop anything new. That, however, is predicated upon innovators playing fairly. In other words, they cannot seek patent protection for things that are not patentable. Yet, some pharmaceutical companies are doing just that.
The protection of intellectual property is one of the biggest challenges facing the technology industry. Somewhat hostile foreign powers, like China, are actively stealing it. What can the United States do to protect its own IP? ACSH interviewed Patrick Kilbride, Senior VP of the Global Innovation Policy Center, seeking answers.
With the hope of increasing accessibility for a burdensome medical issue, can this application actually make a dent as a screening or diagnostic tool?
With fountain-of-youth and cancer-cure promises galore, what's actually transformative -- and happening now -- might surprise you. The key is where to look.
Despite having yet to save the life of a mouse, an Israeli company is making grandiose pronouncements. However, if you look beyond the hype the medical approach is actually pretty interesting.
Synthetic biology is like genetic engineering on steroids. Using cutting-edge computational design, synthetic biology aims to design novel biological molecules -- or even entire metabolic systems. Here's a plan to use this new technology to develop a world-changing treatment for Celiac disease.
Medicare doesn't dispute how much pharmaceutical companies charge for their drugs. This laxity has inevitably led to the program being fleeced by them – to the tune of over a billion dollars. And that's just for a drug that doesn't even need to be in use.
At long last, the FDA approved biotech salmon, AquaAdvantage, which is bred to grow to twice the size of other fish. But in contrast to every scientific study and advisory, the editorial board of The New York Times writes that the genetically-modified fish should be labelled. We take issue with that position.
While a field trial of genetically-modified wheat failed to reach its goal (of repelling destructive aphids), the progress made in incorporating relevant genetic traits into the wheat genome will yield more information for better outcomes later.
Dr. Robert Fraley, a top researcher at Monsanto, was recently quoted in a Nebraska Radio Network article, stating that he believed that those opposing GMOs are extreme voices and that most people are in the middle. Dr. Fraley, who is often referred to as the father of agricultural biotechnology, according to